Julien Champagne

Julien Champagne

Auto-generated profile, based on publicly available information

Julien Champagne

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
OBOsnat Bartok
Osnat Bartok
APAbhijeet Pataskar
Abhijeet Pataskar
RNRemco Nagel
Remco Nagel
MLMaarja Laos
Maarja Laos
EGEden Goldfarb
Eden Goldfarb
RAReuven Agami
Reuven Agami

9 March 2022 in Nature
Verified
Journal Article
Open access
PDF file
APAbhijeet Pataskar
Abhijeet Pataskar
JCJulien Champagne
Julien Champagne
RNRemco Nagel
Remco Nagel
JKJuliana Kenski
Juliana Kenski
MLMaarja Laos
Maarja Laos
RAReuven Agami
Reuven Agami
Activated T cells secrete interferon-γ, which triggers intracellular tryptophan shortage by upregulating the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme1–4. Here we show that despite tryptophan depletion, in-frame protein synthesis continues across tryptophan codons. We identified tryptophan-to-phenylalanine codon reassignment (W>F) as the major event facilitating this process, and pinpointed tryptophanyl-tRNA synthetase (WARS1) as its source. We call these W>F peptides ‘substitutants’ to distinguish them from genetically encoded mutants. Using large-scale proteomics analyses, we demonstrate W>F substitutants to be highly abundant in multiple cancer types. W>F substitutants were enriched in tumours relative to matching adjacent normal tissues, and were associated with increased IDO1 expression, oncogenic signalling and the tumour-immune microenvironment. Functionally, W>F substitutants can impair protein activity, but also expand the landscape of antigens presented at the cell surface to activate T cell responses. Thus, substitutants are generated by an alternative decoding mechanism with potential effects on gene function and tumour immunoreactivity.

15 September 2014 in Development
Verified
Journal Article
Open access
PDF file
BMBrigitte Moniot
Brigitte Moniot
SUSafdar Ujjan
Safdar Ujjan
JCJulien Champagne
Julien Champagne
HHHiroyuki Hirai
Hiroyuki Hirai
KAKosuke Aritake
Kosuke Aritake
BBBoizet-Bonhoure Brigitte
Boizet-Bonhoure Brigitte
Through intercellular signalling, the somatic compartment of the foetal testis is able to program primordial germ cells to undergo spermatogenesis. Fibroblast growth factor 9 and several members of the transforming growth factor β superfamily are involved in this process in the foetal testis, counteracting the induction of meiosis by retinoic acid and activating germinal mitotic arrest. Here, using in vitro and in vivo approaches, we show that prostaglandin D2 (PGD2), which is produced through both L-Pgds and H-Pgds enzymatic activities in the somatic and germ cell compartments of the foetal testis, plays a role in mitotic arrest in male germ cells by activating the expression and nuclear localization of the CDK inhibitor p21Cip1 and by repressing pluripotency markers. We show that PGD2 acts through its Dp2 receptor, at least in part through direct effects in germ cells, and contributes to the proper differentiation of male germ cells through the upregulation of the master gene Nanos2. Our data identify PGD2 signalling as an early pathway that acts in both paracrine and autocrine manners, and contributes to the differentiation of germ cells in the foetal testis.

29 July 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
RNRemco Nagel
Remco Nagel
APAbhijeet Pataskar
Abhijeet Pataskar
JCJulien Champagne
Julien Champagne
RAReuven Agami
Reuven Agami
Immune-checkpoint blockade therapy has been successfully applied to many cancers, particularly tumors that harbor a high mutational burden and consequently express a high abundance of neoantigens. However, novel approaches are needed to improve the efficacy of immunotherapy for treating tumors that lack a high load of classic genetically derived neoantigens. Recent discoveries of broad classes of nongenetically encoded and inducible neoepitopes open up new avenues for therapeutic development to enhance sensitivity to immunotherapies. In this review, we discuss recent work on neoantigen discovery, with an emphasis on novel classes of noncanonical neoepitopes.

10 April 2024 in EMBO Reports
Verified
Journal Article
Open access
MDMatheus H Dias
Matheus H Dias
VLVladyslava Liudkovska
Vladyslava Liudkovska
JNJasmine Montenegro Navarro
Jasmine Montenegro Navarro
LGLisanne Giebel
Lisanne Giebel
JCJulien Champagne
Julien Champagne
MCMaciej Ciesla
Maciej Ciesla
Perturbation of protein phosphorylation represents an attractive approach to cancer treatment. Besides kinase inhibitors, protein phosphatase inhibitors have been shown to have anti-cancer activity. A prime example is the small molecule LB-100, an inhibitor of protein phosphatases 2A/5 (PP2A/PP5), enzymes that affect cellular physiology. LB-100 has proven effective in pre-clinical models in combination with immunotherapy, but the molecular underpinnings of this synergy remain understood poorly. We report here a sensitivity of the mRNA splicing machinery to phosphorylation changes in response to LB-100 in colorectal adenocarcinoma. We observe enrichment for differentially phosphorylated sites within cancer-critical splicing nodes of U2 snRNP, SRSF and hnRNP proteins. Altered phosphorylation endows LB-100-treated colorectal adenocarcinoma cells with differential splicing patterns. In PP2A-inhibited cells, over 1000 events of exon skipping and intron retention affect regulators of genomic integrity. Finally, we show that LB-100-evoked alternative splicing leads to neoantigens that are presented by MHC class 1 at the cell surface. Our findings provide a potential explanation for the pre-clinical and clinical observations that LB-100 sensitizes cancer cells to immune checkpoint blockade.

27 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAlexander Kowar
Alexander Kowar
JBJonas P. Becker
Jonas P. Becker
RPRossella Del Pizzo
Rossella Del Pizzo
ZTZhiwei Tang
Zhiwei Tang
JCJulien Champagne
Julien Champagne
FLFabricio Loayza-Puch
Fabricio Loayza-Puch
Mitosis is a critical phase of the cell cycle and a vulnerable point where cancer cells can be disrupted, causing cell death and inhibiting tumor growth. Challenges such as drug resistance persist in clinical applications. During mitosis, mRNA translation is generally downregulated, while non-canonical translation of specific transcripts continues. Here, we show that mitotic cancer cells redistribute ribosomes toward the 5′ untranslated region (5′ UTR) and beginning of the coding sequence (CDS), enhancing translation of thousands of upstream open reading frames (uORFs) and upstream overlapping open reading frames (uoORFs). This mitotic induction of uORF/uoORF enriches human leukocyte antigen (HLA) presentation of non-canonical peptides on the surface of cancer cells after mitotic inhibitor treatment. Functional assays indicate these epitopes provoke cancer-cell killing by T cells. Our findings highlight the therapeutic potential of targeting uORF/uoORF-derived epitopes with mitotic inhibitors to enhance immune recognition and tumor cell elimination.